Rewind Therapeutics

Rewind Therapeutics is developing novel re-myelinating therapies for patients suffering from multiple sclerosis and other myelin-related diseases

[Rewind Therapeutics @Rewind_Tx]

We warmly welcome our new Chief Scientific Officer Dr. Irene Knuesel. Irene has an outstanding track record in neuroimmunology and neurodegeneration and we look forward to working with her!

https://t.co/abHUG1Jw33

[Rewind Therapeutics @Rewind_Tx]

We have some very exciting news to share with you on this Wednesday morning! Rewind Therapeutics has selected Dr. Anja Harmeier to join us as our new CEO. We look forward to a successful journey with her. Welcome on board!
See the full press release here: https://t.co/Lce5AurCEA

[Rewind Therapeutics @Rewind_Tx]

Proud to announce that our Executive Chairman @jimvanheusden will be presenting at the 21st #BioEquity Europe Global Digital event next week (17-19 May), hosted by @BioCentury and @EBDgroup. Jim's presentation is under the “Next Wave Track”. Check it out!
https://t.co/WePcUiGQxZ

[MEDiSTRAVA, an Inizio Company @MEDiSTRAVA_]

@Rewind_Tx, which is developing innovative first-in-class #remyelinating therapies for #myelin-related diseases such as #multiplesclerosis, appoints industry veteran Kees Been as a Non-Executive Director
https://t.co/ssk0LdNNhO

[flanders.bio @flandersbio]

Rewind Therapeutics appoints Biopharmaceutical Industry Veteran Kees Been as Non-Executive Director.
https://t.co/2QnovuFTnl

[[iito] Life Science @iitoLifeScience]

Rewind Therapeutics appoints Kees Been as Non-Executive Director https://t.co/KgmqsMQ8MH @Rewind_Tx More Benelux life science business news at [LSBNL] at https://t.co/6qaXvuz2qI

[Rewind Therapeutics @Rewind_Tx]

Very happy to welcome industry veteran Kees Been to our Board of Directors

[BioMed21 Collaboration @BioMed_21]

This looks exciting! Congratulations to @Rewind_Tx awarded almost €3million in an innovative collaboration to develop drug screening assays with #Human stem cell models and devise chip-based studies for nerve myelination studies @LeuvenU @imec_int

https://t.co/qQuBmo0A1W

[Rewind Therapeutics @Rewind_Tx]

Our CEO Ian Reynolds will be presenting today at 4.00 pm (Room Vivaldi 1) at the #BioEquity meeting in Barcelona. See you there!

[saar sinnaeve @ssinnaeve]

België is bij de wereldtop in medische biotechnologie. De Tijd brengt het hele ecosysteem in kaart. https://t.co/r3Zpwdjv6K

[saar sinnaeve @ssinnaeve]

Biotech, de mirakeloplossing? Leuvense start-up vecht tegen superbacteriën https://t.co/KSS5XEVv8R

[Rewind Therapeutics @Rewind_Tx]

We’re here, so let’s meet up when you want to know more about remyelination and Rewind’s approach. #BIOEurope

[EBD Group @EBDgroup]

Welcome to our #BIOEurope attendees! Get ready to make this the biggest year yet 🤝📈

[Rewind Therapeutics @Rewind_Tx]

Our CEO will be at @ECTRIMS 2018. Let’s talk!

[ECTRIMS @ECTRIMS]

#ECTRIMS2018 Hall A is filling for opening https://t.co/XVF1wcLTeZ

[saar sinnaeve @ssinnaeve]

Biotechmecenas Mariën opent nieuwe Gentse biotechcampus https://t.co/04AWtRRpTc

[Jim Van heusden @jimvanheusden]

Very happy to welcome world leading experts Prof Brück, Prof Comi and Dr Wang to @Rewind_Tx SAB

[MEDiSTRAVA, an Inizio Company @MEDiSTRAVA_]

@Rewind_Tx builds Scientific Advisory Board to accelerate its development of new therapies for myelin-related diseases https://t.co/Tejzl1ogue

[Rewind Therapeutics @Rewind_Tx]

Rewind Therapeutics builds Scientific Advisory Board to accelerate its development of new therapies for myelin-related diseases

[Jim Van heusden @jimvanheusden]

I'm thrilled to welcome Ian J. Reynolds as CEO of Rewind Therapeutics. Ian is a smart, passionate and extremely talented drug-hunter in the world of neuroscience. He has a strong and deep track record of novel drug development.

[Rewind Therapeutics @Rewind_Tx]

Rewind Therapeutics appoints leading neuroscience drug developer Ian J. Reynolds as Chief Executive Officer

[Rewind Therapeutics @Rewind_Tx]

Today is world MS day #bringinguscloser